You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 5, 2019

Update on Thailand’s “Delisting” of Marijuana and Hemp from the Scope of Category 5 Narcotics

Subscribe to Updates

On Friday August 30, 2019, a Notification of the Thai Ministry of Public Health (“MOPH Notification”) was published in the Government Gazette. The MOPH Notification went into effect on August 31, 2019, one day after its publication.

This MOPH Notification outlines another Thai Government initiative in connection with the free cannabis policy, this time carving out further aspects of marijuana and hemp use from the stringent regulations under the Narcotics Act.

Marijuana is described in the MOPH Notification as plants of the cannabis genus, including all parts of a marijuana plant and the substances or chemicals found in a marijuana plant. Hemp is defined as plants falling within Cannabis sativa L. Subsp. sativa, including all parts of a hemp plant.

In fact, marijuana and hemp are not entirely “delisted” from the classification of Category 5 Narcotics as identified in the Narcotics Act. While these plants are still listed as Narcotics, the MOPH Notification serves to prescribe “exceptions”, meaning aspects and particulars of marijuana and hemp related products that are not considered Narcotics.

The new exceptions are summarized below.

For both marijuana and hemp

(1) Marijuana or hemp stalks, stem cores, and fibers are excepted, if dried. The products made of such dry parts are excepted, as well.

(2) Cannabidiol (CBD) extracted from marijuana or hemp is excepted if having at least 99% purity and no more than 0.01 percent by weight of tetrahydrocannabinol (THC).

(3) Extracts of marijuana or hemp having CBD as the main constituent and no more than 0.2% by weight of THC, which are considered “drugs” as per the Drug Act, or Herbal Products as identified in the Herbal Products Act.

For hemp only

(4) Hemp seeds or hemp seed oil, which are considered Food as identified in the Food Act.

(5) Hemp seed oil or hemp seed extracts, which are considered Cosmetics as identified in the Cosmetics Act.

In other words, hemp products according to the above descriptions may now be classified as Medicinal Drugs, Herbal Products, Food, or Cosmetics under their respective regulations. Marijuana may now be classified as Medicinal Drugs or Herbal Products only.

It should be noted that during the first five years under the MOPH Notification of August 30, 2019, the exceptions per (3) – (5) above apply only to domestic production by a licensee under the respective laws. This means the importation of products that would otherwise fall within those exceptions would still be regulated by the Narcotics Act—highlighting the Thai Government’s agenda in protecting Thai business operators.

According to the Thai Ministry of Public Health’s public conference held on September 2, 2019, the exception per (2) above for high-purity extracts (99% or higher of CBD; 0.01% or lower of THC) are intended to cover laboratory-grade standard extracts. For the (3) – (5) exceptions, the Thai FDA will later issue further rules under the Drug Act, the Herbal Products Act, the Cosmetics Act, or the Food Act to specifically accommodate the use of marijuana and hemp extracts in the respective products.

Moreover, amendments to the previous Industrial Hemp Regulation of 2016 are in the pipeline. The purpose of these amendments are to include non-public entities as parties having standing to apply for industrial hemp licenses.

Abridged Translation of the MOPH Notification

Remarks: The present MOPH Notification (2019) does not affect Items Nos. 2–4 on this list, which were prescribed by the previous MOPH Notification of 2018. Said unaffected items are:

No. 2:    Kratom (Mitragyna speciose);

No. 3:    Opium poppies (Papaver somniferum L. and Papaver bracteatum Lindl.); and

No. 4:    Psilocybin mushrooms.

Details about the above Nos. 2–4 are omitted from this update.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
Read More
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
Read More
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More